摘要
目的对肝硬化并发肝性脑病患者的载脂蛋白AI、B的临床检测意义进行探讨、分析。方法对65例肝硬化患者(观察组)(其中19例并发肝性脑病)以及65例健康人(对照组)的血液样本进行对比分析。结果观察组的血清载脂蛋白AI、B水平均比对照组明显降低(P<0.01);并发肝性脑病的患者血清载脂蛋白AI、B水平及白蛋白水平明显降低(P<0.05);19例并发肝性脑病病情好转患者血清载脂蛋白AI上升明显(P<0.01),病情恶化血清载脂蛋白AI明显下降(P<0.05),治疗前后血清载脂蛋白B水平差异无统计学意义。结论对血清载脂蛋白AI、B进行动态检测可以帮助预测肝硬化并肝性脑病患者预后,结合临床判断提高治疗的针对性,使疗效进一步提升。
Objective To explore and analyze the clinical detection value of apolipoprotein AI and 13 in patients with liver cirrhcxsis complicate by hepatic encephalopathy. Methods The blood samples of 65 patients with liver cirrhosis in observation group （including 19 cases of complicated by hepatic encephalopathy） and 65 healthy individuals in control group were compared and analyzed. Results Serum apolipoprotein AI and B levels were both significantly lower than those of control group （P〈 0.01 ）. Serum apolipoprotein AI, B and albumin levels in those patients complicated by hepatic encephalopathy were significantly decreased （P〈 0.05）. Among 19 patients complicated by hepatic encephalopathy, serum apolipoprotein AI level in the patients with improved condition was increased significantly （P 〈 0. 01 ）, while that in the deteriorating patients was decreased signifcantly （P 〈 0.05）. There was no statistically significant difference in serum level of apolipoprotein B between before and after the treatment. Conclusions Dynamic detection of serum apolipoprotein AI and B is conducive to predicting the prognosis of liver cirrhosis patients complicated by hepatic encephalopathy. Serum apolipoprotein AI and B detection combined with the clinical diagnosis could improve the targeted therapy so as to further enhance the therapeutic efficacy.
出处
《实用预防医学》
CAS
2012年第2期256-257,共2页
Practical Preventive Medicine
关键词
肝硬化
肝性脑病
载脂蛋白AI、B
Liver cirrhosis
Hepatic encephalopathy
Apolipoprotein AI and B
